Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Brainstorm Cell Therapeutics Inc. (BCLI) had Return on Tangible Equity of 103.22% for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-10.31M |
|
-- |
|
-- |
|
$9.95M |
|
$-9.95M |
|
$-0.35M |
|
$-10.31M |
|
$-10.31M |
|
$-10.31M |
|
$-10.31M |
|
$-10.31M |
|
$-10.31M |
|
$-9.95M |
|
$-9.75M |
|
9.27M |
|
9.27M |
|
$-1.11 |
|
$-1.11 |
|
| Balance Sheet Financials | |
$0.31M |
|
$0.23M |
|
$0.71M |
|
$1.02M |
|
$11.01M |
|
-- |
|
-- |
|
$11.01M |
|
$-9.98M |
|
$-9.98M |
|
$-9.98M |
|
11.04M |
|
| Cash Flow Statement Financials | |
$-6.97M |
|
$0.00M |
|
$6.88M |
|
$0.37M |
|
$0.28M |
|
$-0.10M |
|
$1.52M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
0.03 |
|
-- |
|
-- |
|
-- |
|
-0.10 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-6.97M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
103.22% |
|
|
Return on Tangible Equity |
103.22% |
-1008.51% |
|
103.22% |
|
$-0.90 |
|
$-0.75 |
|
$-0.75 |
|